Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEAM DOWN study of standard care for depression, catatonia, and DSRD in Down syndrome
NL-OMON57635Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of escitalopram and lorazepam in major depressive disorder (MDD), catatonia and Down syndrome regression disorder (DSRD), sponsored by Amsterdam University Medical Center. Primary endpoint: Anxiety, Depression and Mood Scale. Started Oct 2025; status: recruiting.
02
Drugs
escitalopramlorazepam
03
Conditions
major depressive disorder (MDD)catatoniaDown syndrome regression disorder (DSRD)
Beyond the preview
Go deeper on NL-OMON57635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57635.